Zobrazeno 1 - 10 of 198 pro vyhledávání: '"WR Gerritsen"'
2
Granulocyte colony-stimulating factor (CSF) but not interleukin-1 (IL- 1), IL-3, and granulocyte-macrophage CSF protect bone marrow progenitor cells from suppression by allosensitized cytotoxic T cells
Autor: WR Gerritsen, RJ O'Reilly
Publikováno v: Blood. 84:1906-1912
The major immunological reactions after an allogeneic bone marrow transplantation (BMT) are graft rejection and graft-versus-host disease (GVHD). GVHD can be prevented by T-cell depletion of the allogeneic BM graft, but the beneficial effect of T-cel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7d734a276f0525b566a603d6ff8b50d
https://doi.org/10.1182/blood.v84.6.1906.bloodjournal8461906
Zobrazit plný text záznamu
3
Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization
Autor: JH Bourhis, R.J. O'Reilly, John F. Donohue, Hugo Castro-Malaspina, J Bauman, Nancy A. Kernan, WR Gerritsen, Suresh C. Jhanwar
Publikováno v: Blood. 80:217-224
Conflicting results have been published on whether or not myelodysplastic syndromes (MDS) affect all cell lineages. Involvement of myeloid and erythroid cell lineages has been regularly observed, but it remains controversial whether the different lym
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c67bb86137fa142902c728114f5359
https://doi.org/10.1182/blood.v80.1.217.bloodjournal801217
Zobrazit plný text záznamu
4
Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
Autor: Grill, J., Vw, Beusechem, Valk, P., Cmf, Dirven, Leonhart, A., Ds, Pherai, Hidde Haisma, Hm, Pinedo, Dt, Curiel, Wr, Gerritsen
Publikováno v: University of Groningen
Adenoviral-mediated gene transfer is suboptimal in human glioma and limits in vivo gene therapy approaches. There is a need for targeted vectors able to enhance gene transfer into the tumor as well as to lower the viral load in the surrounding normal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2c3d5acc8fea2e5893e76d887c97b6bd
https://research.rug.nl/en/publications/6502706c-2af3-4158-abbc-cc4b5397f2b5
Zobrazit plný text záznamu
6
Cloning and characterization of human liver cytosolic beta-glycosidase
Autor: Graaf, M., Ic, Veen, Ih, Meulen-Muileman, Wr, Gerritsen, Hm, Pinedo, Hidde Haisma
Publikováno v: University of Groningen
Cytosolic beta-glucosidase (EC 3.2.1.21) from mammalian liver is a member of the family 1 glycoside hydrolases and is known for its ability to hydrolyse a range of beta-D-glycosides, including beta-D-glucoside and beta-D-galactoside. We therefore ref
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::99eda8268dad55caf33233689af18505
https://research.rug.nl/en/publications/58d9997b-44d3-4f96-b663-ad4ec6c8871b
Zobrazit plný text záznamu
7
Akademický článek
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
Autor: van Wilpe S; Department of Medical Oncology., Kloots ISH; Department of Medical Oncology., Slootbeek PHJ; Department of Medical Oncology., den Brok M; Department of Medical Oncology., Westdorp H; Department of Medical Oncology., Franken MD; Department of Medical Oncology., Coskunturk M; Department of Medical Oncology., Osinga T; Department of Medical Oncology., Bloemendal H; Department of Medical Oncology., Adema G; Department of Radiation Oncology., Smeenk RJ; Department of Radiation Oncology., Nagarajah J; Department of Medical Imaging., van Ipenburg J; Department of Pathology., Kroeze LI; Department of Pathology., Ligtenberg MJL; Department of Pathology; Department of Human Genetics., Schalken J; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology., Mehra N; Department of Medical Oncology. Electronic address: Niven.mehra@radboudumc.nl.
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Dec; Vol. 35 (12), pp. 1126-1137. Date of Electronic Publication: 2024 Sep 16.
Zobrazit plný text záznamu
8
Akademický článek
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
Autor: de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: r.dewit@erasmusmc.nl., Vaughn DJ; Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Fradet Y; Department of Surgery/Urology, CHU de Québec-Université Laval Research Center, Quebec, QC, Canada., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Climent MA; Department of Medical Oncology, Valencian Institute of Oncology (IVO Foundation), Valencia, Spain., Necchi A; Department of Medical Oncology, Vita-Salute San Raffaele University and IRCCS Ospedale San Raffaele, Milan, Italy., Petrylak DP; Department of Internal Medicine/Medical Oncology, Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA., Gerritsen WR; Department of Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gurney H; Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia., Quinn DI; Developmental Therapeutics Program, USC Norris Comprehensive Cancer Center and Division of Cancer Medicine and Blood Diseases, Keck Medicine of USC, Los Angeles, CA, USA., Culine S; Department of Medical Oncology, Saint-Louis Hospital, Paris, France., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian, New York, NY, USA., Bajorin DF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Choueiri TK; Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Xu J; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA., Imai K; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA., Homet Moreno B; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA., Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute and IMIM Research Institute, Harvard Medical School, Boston, MA, USA., Lee JL; Division of Oncology, Department of Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea.
Publikováno v: European urology [Eur Urol] 2024 Aug 21. Date of Electronic Publication: 2024 Aug 21.
Zobrazit plný text záznamu
9
Akademický článek
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Autor: Graff JN; Oregon Health and Science University, Portland, OR, USA. graffj@ohsu.edu., Hoimes CJ; Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.; Duke University School of Medicine, Durham, NC, USA., Gerritsen WR; Radboud University Medical Center, Nijmegen, Netherlands., Vaishampayan UN; University of Michigan and Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Elliott T; NHS Lothian, Edinburgh, UK., Hwang C; Henry Ford Health System, Detroit, MI, USA., Ten Tije AJ; Amphia Hospital, Breda, Netherlands., Omlin A; Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland., McDermott RS; Tallaght University Hospital, Dublin, Ireland., Fradet Y; CHU de Québec-Université Laval, Québec City, QC, Canada., Tagawa ST; Weill Cornell Medical College, New York, NY, USA., Kilari D; Medical College of Wisconsin, Milwaukee, WI, USA., Ferrario C; Jewish General Hospital, Montreal, QC, Canada., Uemura H; Yokohama City University Medical Center, Yokohama, Japan., Jones RJ; University of Glasgow, Glasgow, UK., Fukasawa S; Chiba Cancer Center, Chiba, Japan., Peer A; Rambam Health Care Campus, Haifa, Israel., Niu C; MSD China, Beijing, China., Poehlein CH; Merck & Co., Inc., Rahway, NJ, USA., Qiu P; Merck & Co., Inc., Rahway, NJ, USA., Suttner L; Merck & Co., Inc., Rahway, NJ, USA., de Wit R; Erasmus University Medical Center, Rotterdam, Netherlands., Schloss C; Merck & Co., Inc., Rahway, NJ, USA., de Bono JS; The Royal Marsden Hospital NHS Foundation Trust and the Institute of Cancer Research, London, UK., Antonarakis ES; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.
Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Aug 12. Date of Electronic Publication: 2024 Aug 12.
Zobrazit plný text záznamu
10
Akademický článek
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Autor: Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van Wilpe S; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Geerlings MJ; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., von Rhein D; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands., Kloots ISH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Westdorp H; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Coskuntürk M; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands., van Ipenburg JA; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van der Heijden AG; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Hofste T; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Weiss MM; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Ligtenberg MJL; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Niven.mehra@radboudumc.nl.
Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Apr; Vol. 7 (2), pp. 282-291. Date of Electronic Publication: 2023 Sep 04.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje